POLEN

A PREOPERATIVE “WINDOW-OPPORTUNITY”, MULTICENTER, PHARMACOKINETIC-PHARMACODYNAMIC STUDY TO EVALUATE THE INHIBITORY EFFECTS OF SINGLE AGENT AZD2281 (OLAPARIB), IN PATIENTS WITH EARLY-STAGE ENDOMETRIAL CARCINOMA.

​

THE PRIMARY OBJECTIVE OF THIS STUDY IS TO IDENTIFY, IN HUMAN TUMOUR SAMPLES, BIOMARKER CHANGES ASSOCIATED TO SHORT EXPOSURE TO AZD2281 AS POTENTIAL PREDICTORS OF ACTIVITY IN ENDOMETRIAL CARCINOMA (EC). 

​

THIS IS AN EXPLORATORY STUDY WITH A BIOLOGICAL PRIMARY ENDPOINT. CLINICAL EFFICACY OR SAFETY ARE NOT A PRIMARY OBJECTIVE OF THE STUDY.

​

​

POLEN AT CLINICALTRIALS.GOV